HDL Therapeutics

Executive Summary

HDL Therapeutics is a Houston-based biotechnology company dedicated to revolutionizing the treatment of atherosclerosis by harnessing the power of HDL ("good cholesterol"). The company has developed an approved therapy that actively regresses arterial plaques, moving beyond traditional disease management to offer a direct treatment for cardiovascular conditions. Its platform leverages a proprietary approach to enhance HDL function, potentially reducing the burden of atherosclerotic cardiovascular disease (ASCVD), which remains the leading cause of morbidity and mortality globally. With a focus on addressing a large unmet need in high-risk patients who continue to experience events despite standard lipid-lowering therapies, HDL Therapeutics targets a significant market opportunity. The company's approved status provides a foundation for commercial growth and further clinical development, positioning it to capture value in the cardiovascular therapeutics space.

Upcoming Catalysts (preview)

• Q4 2026Publication of pivotal trial results demonstrating plaque regression80% success
• Q2 2027FDA approval for expanded indication in high-risk ASCVD patients70% success
• Q3 2026Strategic partnership for commercial distribution in key markets75% success